DTaP-HBV rDNA-Hib-IPV Sanofi - Biotech, Pharma and Life Science Channel
PubMed Articles
Longidorus aetnaeus Roca, Lamberti, Agostinelli & Vinciguerra, 1986 is reported for the first time from Iran and Ajaria (Georgia). Morphological and morphometric data are provided for two Iranian and...
A population of Xiphinema macroacanthum Lamberti, Roca & Agostinelli, 1989 originating from olive orchards in Brindisi, Italy and containing both adults and all juvenile stages, is described and illus...
Although larvae of the genus Trichinella are the most common parasite species detected in vertebrate muscles using artificial digestion, nematode larvae belonging to other genera are sometimes detecte...
The seasonal and spatial diversity of picocyanobacteria (Pcy) in lakes of the Great Mazurian Lakes (GLM) system was examined by DGGE analysis of molecular markers derived from the 16S–23S intern...
OBJECTIVE: Aflibercept (Zaltrap(®)) is a novel antiangiogenic agent that binds to vascular endothelial growth factor (VEGF) and inhibits VEGF-dependent tumor growth. We aimed to characterize the popu...
BACKGROUND AND OBJECTIVE: There is a paucity of data in relation to the possible emergence of triclosan (TCS)-resistant bacteria following long-term exposure to TCS toothpaste. Therefore, this study i...
Multi-regional clinical trials have been widely used for efficient global new drug developments. Both a fixed-effect model and a random-effect model can be used for trial design and data analysis of a...
A total of 515 yeast strains were isolated from the nasal smears of Queensland koalas and their breeding environments in Japanese zoological parks between 2005 and 2012. The most frequent species in t...
AIMS/HYPOTHESIS: In vitro, insulin glargine (A21Gly,B31Arg,B32Arg human insulin) has an insulin receptor (IR) profile similar to that of human insulin, but a slightly higher affinity for the IGF-1 rec...
This study assessed and compared the immunogenicity of various immunization strategies in mice using combinations of recombinant DNA (pCCMp24) and recombinant attenuated vaccinia virus Tian Tan (rddVT...
News Articles
Sanofi planning filings on top-line JAKARTA read-out
Top-line results for the Phase III JAKARTA trial of Sanofi's JAK 2 inhibitor SAR302503 have come in positive and on schedule in myelofibrosis. Sanofi says the study met the primary endpoint, which is...
Sanofi stays in Toulouse...for now,
Sanofi stays in Toulouse...for now,
PARIS, May 17, 2013 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that the pivotal study, JAKARTA, examining the selective JAK2 inhibitor SAR302503 for myelofibrosis (...
India's New Price Controls To Hit 652 Essential Drugs, Cutting Profits
India's new list of price-regulated essential drugs set to take effect in mid-June will cover 652 bulk drugs and their formulations, with GlaxoSmithKline and Sanofi Aventis to be the most adversely af...
Sanofi's SAR302503 meets in myelofibrosis
Sanofi (Euronext:SAN; NYSE:SNY) said once-daily 400 and 500 mg doses of oral SAR302503 each met the primary endpoint in the Phase III JAKARTA trial to treat primary myelofibrosis (PMF), post-polycythe...
Beware copycat probes after Sanofi generics case
This week's €40.6 million fine against Sanofi could presage further investigations into the legality of techniques used by pharmaceutical companies to protect their franchises from generic comp...
REFILE-Sanofi says will back overhaul of Toulouse research site
(Changes 'keep' to 'back overhaul of' in headline; changes wording of paragraph 7 to remove reference to retaining site)
Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
French drug major Sanofi (Euronext: SAN) and NYSE: SNY) this morning (May 17) revealed that the pivotal study, JAKARTA, examining the selective JAK2 inhibitor SAR302503 for myelofibrosis (MF), met its...
Sanofi says will keep Toulouse research site
PARIS (Reuters) - Sanofi said it would overhaul rather than exit its Toulouse research site, as it seeks to break an impasse with the French government which opposed the drugmaker's reorganization pla...
Sanofi's Abnormal Blood Cell Production Inhibitor Meets Goal In Phase III
PARIS (dpa-AFX) - French drugmaker Sanofi (SNY, SNYNF.PK) Friday announced that the Phase III study of Myelofibrosis inhibitor SAR302503 recorded greater 35 percent reduction in spleen volume, con...
Companies
Zalicus focuses its internal drug development efforts on pain and immuno-inflammatory diseases. Our pipeline for pain includes Exalgo⢠(hydromorphone HCl) extended-release ta...
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Pa...
Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals t...
Bionest Partners Inc. provides strategy consulting services exclusively for the life science industries to help pharmaceutical, biopharmaceutical, diagnostics, biotechnology, and...
Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forwardâs products and services have been utilized in o...
Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other s...
GENFIT (Paris:ALGFT) is a biopharmaceutical company focused on the Discovery and Development of drug candidates in strategic therapeutic fields linked to cardiometabolic and neuro...
Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forward's products and services have been utilized in over 1...
EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, is a leader in the US biopharmaceutical arena, integrating cutting-edge science with unparalleled patient support...
EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, is a leader in the US biopharmaceutical arena, integrating cutting-edge science with unparalleled patient support...
Clinical Trials
DTaP-HB-PRP~T combined vaccine is being developed in order to comply with expanding programs for immunization in infancy, while offering the benefit of a reduced number of injections, and...
Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of Age
Currently, there is no 5-component acellular pertussis vaccine licensed for the 5th dose in US children aged 4 to 6 years.This study is aimed at providing evidence of sero-protection, boos...
It is well recognized that older adults can contract pertussis, suffer its complications, and unwittingly transmit it to close contacts, which may well include infants too young to have re...
The purpose of this trial is to clinically confirm that the manufacturing process of the final bulk products of the investigational DTaP-IPV-HB-PRP~T vaccine is consistent. The primary ob...
Open-Label Study of H5 Vaccine in Participants of Protocol 04-077
This study may provide safety information on a flu vaccine given to children and may provide immunogenicity information to add to what was collected in a previous flu vaccine study. Partic...
The purpose of the study is to provide immunogenicity and safety data of the investigational hexavalent vaccine when it is given concomitantly (the same day at separate injection sites) wi...
PR5I, a hexavalent pediatric combination vaccine is being developed to reduce the number of injections during the first 2 years of life while providing a complete course of immunization ag...
The purpose of this study is to document the immunological response to the investigational hexavalent vaccine at the 6, 10, and 14 weeks schedule The primary objective is to demonstrate t...
Immunogenicity and Safety of Tetraxim Versus Local DTP + IPV
The present clinical study will assess the immunogenicity and reactogenicity of Sanofi Pasteur's DTaP-IPV combined vaccines as a three-dose primary vaccination at 2, 4 and 6 months of age...
To demonstrate that the immune response to hepatitis B antigen of the DTaP IPV HB PRP~T is non-inferior to that of the association of PENTAXIM™ and ENGERIX B® one month after a three do...
Videos
Medical and Biotech [MESH] Definitions
Actinobacteria
Class of BACTERIA with diverse morphological properties. Strains of Actinobacteria show greater than 80% 16S rDNA/rRNA sequence similarity among each other and also the presence of certain signature nucleotides. (Stackebrandt E. et al, Int. J. Syst. Bacteriol. (1997) 47:479-491)
Dna, Ribosomal Spacer
The intergenic DNA segments that are between the ribosomal RNA genes (internal transcribed spacers) and between the tandemly repeated units of rDNA (external transcribed spacers and nontranscribed spacers).
